Motexafin gadolinium

CAS: 246252-06-2 F: C52H72GdN5O14 W: 1148.40

Motexafin gadolinium (PCI 0120) is a potent antitumor agent. Motexafin gadolinium is a specific texaphyrin in complex wi

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Motexafin gadolinium (PCI 0120) is a potent antitumor agent. Motexafin gadolinium is a specific texaphyrin in complex with gadolinium(III). Motexafin gadolinium increases intracellular ROS production. Motexafin gadolinium enhances sensitivity of tumor cells to ionizing radiation[1][2][3].
Invitro	Motexafin gadolinium (50 µM; 22 h) 导致 A549 细胞中的二氯荧光素乙酸盐 (DCFA) 氧化[1]。Motexafin gadolinium (100 µM；4、12 小时) 与 Zn (100 μM) 和抗坏血酸 (100 μM) 结合时，可增加拉莫斯淋巴瘤细胞中细胞内 ROS 的产生和细胞凋亡 (24 小时)[2] .当与锌 (100 μM) 和抗坏血酸 (100 μM) 结合使用时，Motexafin gadolinium (0.01-100 μM) 会剂量依赖性地降低 HF-1 细胞中 p53 蛋白的表达[2]。 Western Blot Analysis[2] Cell Line:
Name	Motexafin gadolinium
CAS	246252-06-2
Formula	C52H72GdN5O14
Molar Mass	1148.40
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Magda D, et al. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol. 2006 Dec;16(6):466-76. [2]. Singh AT, et al. Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. Anticancer Res. 2010 Apr;30(4):1131-6. [3]. Evens AM, et al. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res. 2009 Oct 15;15(20):6462-71.

Nangibotide scrambled peptide